David Hochman is the founder of Orchestra BioMed. Orchestra BioMed has raised $148M in total funding.
David Hochman is the Chairman, CEO, and Founder of Orchestra BioMed, a biotechnology company focused on cardiovascular therapies. He has secured significant strategic capital to extend the company's cash runway and complete pivotal clinical studies. Orchestra BioMed has received FDA breakthrough device designation for its hypertension therapy.
Full founder directory · Investor directory · Company funding database · Fundraising library